Vesugen
Vesugen (Khavinson)
Vesugen (Lys-Glu-Asp, or KED tripeptide) is a synthetic bioregulatory peptide developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. It is a short-chain tripeptide designed to target the vascular endothelium and support blood vessel function. Vesugen is part of the Khavinson bioregulator family of peptides, which are proposed to regulate gene expression in specific tissues.
Starting dose. 500 mcg — Daily
SubQ injection, any time of day. 10-20 day courses, 2-3 cycles per year with 4-6 months between courses (Khavinson protocol). Pin alone or with other bioregulators only.
Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.
How it works
Proposed to act as a gene-regulatory peptide that penetrates cell membranes and interacts with DNA promoter sequences in vascular endothelial cells, modulating expression of genes involved in endothelial nitric oxide synthase (eNOS), prostacyclin production, and vessel wall structural proteins.
May support vascular homeostasis by promoting endothelial cell proliferation and repair while reducing endothelial dysfunction markers. Khavinson's research suggests short peptides can epigenetically regulate tissue-specific gene expression patterns.
The tripeptide sequence (Lys-Glu-Asp) is proposed to have specificity for vascular tissue based on computational modeling of peptide-DNA interactions, distinguishing it from other bioregulators that target different organs.
What to expect
Days 1-7: Peptide-DNA interactions proposed to begin modulating gene expression in vascular endothelial cells. No subjective changes expected.
Evidence
Claims we could not support
No abstract we checked supports these for this molecule at this route. That is not the same as saying they are false — it marks where the evidence is missing.
Exact-molecule abstract evidence. ESearch was run and 3 source-candidate PMIDs were EFetch-checked; no usable exact-molecule abstract sentence was found.
Dose/route: 500 mcg daily; Subcutaneous (SubQ); 10-20 day course. No selected live abstract sentence verified this complete regimen.
Mechanism as written in source JSON. No selected live abstract sentence verified the complete mechanism at the card formulation/route and relevant population/model.
Primary safety claim as written in source JSON. No selected live abstract sentence verified the complete safety claim for this exact formulation and route.
Interactions & stacking
Two different questions: what is documented about running these together, and what is documented about drawing them into the same syringe. A good pharmacological partner can still have to be pinned separately.
Keep separate
Check any specific pair in the Stack & Interaction Checker, which answers both questions separately. Absence of a documented conflict is not evidence of safety.
Pharmacokinetics
5-15 minutes - tiny peptide
SubQ
SubQ (estimated for small peptide)
Post-cycle (epigenetic vascular gene expression changes persist weeks to months per Khavinson theory)
Rapid enzymatic degradation (tripeptidases and aminopeptidases)
Storage. Store refrigerated at 2-8C. Reconstituted solution should be used within 14-28 days.
Regulatory status
Used clinically in Russia. Not FDA-approved. Classified as a research compound in the US and EU. Oral equivalent (Ventfort) available as a supplement in some markets.
Put it to work
Calculate, log & track
Open Vesugen straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.
Open Vesugen in the app →Go deeper
The guide & community
The complete Vesugen walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.
Join the community ↗